efficacy of glp 1 receptor agonists Comparative and safety GLP-1 for weight reduction: A model-based meta-analysis of placebo-controlled trials GLP-1 Receptor Agonist Market Size

GLP-1 receptor agonists can cause a range of potential side effects

Looking at their financials, Novo Nordisk and Eli Lilly have comparable revenue scales in 2022, both ranging between $25 billion and $30 billion

Collectively, these data position GLP-1RAs as promising agents for the management of respiratory diseases, offering both symptomatic relief and potential disease-modifying effects

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

The second article considers problems, side-effects and reasons to avoid GLP-1 and GIP/GLP-1 RAs, while the third reviews their role in weight management